Johnson & Johnson announced a definitive agreement to acquire Novira Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company developing novel therapies for curative treatment of chronic hepatitis B virus (HBV) infection. The acquisition includes Novira's portfolio of novel antivirals, including its lead candidate, NVR 3-778. Financial terms of the transaction have not been disclosed.
http://www.marketwatch.com/story/johnson-johnson-announces-agreement-to-acquire-novira-therapeutics-inc-2015-11-04
More and More competition its always good. what do you thing of novira's NVR 3-778? do you think it might contribute to a final cure?